Cargando…

Buprenorphine Microdosing Cross Tapers: A Time for Change

Buprenorphine is a partial opioid agonist that is Food and Drug Administration (FDA) approved to treat chronic pain and opioid use disorder (OUD). The national prescribing guidelines in the United States (US) recommend that patients transitioning from full opioid agonists to buprenorphine first unde...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raheemullah, Amer, Benhamou, Ori-Michael, Kuo, Jamie, Lembke, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Viewpoint
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778657/ https://www.ncbi.nlm.nih.gov/pubmed/36554317 http://dx.doi.org/10.3390/ijerph192416436

Ejemplares similares

Outpatient Microdose Induction with Transdermal Buprenorphine: A Case Series
por: Menard, Shannon, et al.
Publicado: (2022)

Factors that distinguish opioid withdrawal during induction with buprenorphine microdosing: a configurational analysis
por: K. K., Adams, et al.
Publicado: (2022)

Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach
por: Rozylo, Jennifer, et al.
Publicado: (2020)

Microdosing and standard‐dosing take‐home buprenorphine from the emergency department: A feasibility study
por: Moe, Jessica, et al.
Publicado: (2020)

Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period
por: Lembke, Anna, et al.
Publicado: (2019)

Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method
por: Hämmig, Robert, et al.
Publicado: (2016)

Buprenorphine-based opioid substitution therapy in India: A few observations, thoughts, and opinions
por: Ghosh, Abhishek, et al.
Publicado: (2018)

Microdose induction of buprenorphine-naloxone in a patient using high dose methadone: A case report
por: Menard, Shannon, et al.
Publicado: (2021)

Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper
por: Bozinoff, Nikki, et al.
Publicado: (2022)

por: Raheemullah, Amer
Publicado: (2022)

Medical Residency Interviews: Time for a Change?
por: Teven, Chad M., et al.
Publicado: (2020)

Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers
por: Hutten, Nadia R. P. W., et al.
Publicado: (2019)

Using Microdosing to Induct Patients Into a Long-Acting Injectable Buprenorphine Depot Medication in Low Threshold Community Settings: A Case Study
por: Tay Wee Teck, Joseph, et al.
Publicado: (2021)

Microdosing: Concept, Application and Relevance
por: Tewari, Tushar, et al.
Publicado: (2010)

Asking questions of psychedelic microdosing
por: Cameron, Lindsay P
Publicado: (2021)

Debride and See: Use of Uterine Curette for Wound Bed Debridement before Skin Grafting
por: Duek, Ori Samuel, et al.
Publicado: (2018)

Ca(2+) as a coordinator of skeletal muscle differentiation, fusion and contraction
por: Sinha, Sansrity, et al.
Publicado: (2022)

A systematic study of microdosing psychedelics
por: Polito, Vince, et al.
Publicado: (2019)

The therapeutic potential of microdosing psychedelics in depression
por: Kuypers, Kim P.C.
Publicado: (2020)

Time for a diagnostic sea-change: Rethinking neglected tropical disease diagnostics to achieve elimination
por: Gass, Katherine
Publicado: (2020)

Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls
por: Rootman, Joseph M., et al.
Publicado: (2022)

Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers
por: Rootman, Joseph M., et al.
Publicado: (2021)

Making a Little History with the Chang Gung Cleft Lip Repair
por: Kang, Gavin Chun-Wui, et al.
Publicado: (2015)

Phase 0 - Microdosing strategy in clinical trials
por: Rani, P. Usha, et al.
Publicado: (2008)

Psychedelic microdosing benefits and challenges: an empirical codebook
por: Anderson, Thomas, et al.
Publicado: (2019)

Time to Move On: Redefining Chest Pain Outcomes
por: Weinstock, Michael B., et al.
Publicado: (2019)

Treating hepatitis C virus in children: time for a new paradigm
por: Thorne, Claire, et al.
Publicado: (2015)

Antibiotic resistance: calling time on the ‘silent pandemic’
por: Mendelson, Marc, et al.
Publicado: (2022)

The Future of TDR: The Need to Adapt to a Changing Global Health Environment
por: Carucci, Daniel J., et al.
Publicado: (2008)

The time is now: expedited HIV differentiated service delivery during the COVID‐19 pandemic
por: Wilkinson, Lynne, et al.
Publicado: (2020)

A Change of Heart
por: Kaza, Nandita
Publicado: (2022)

Author Correction: Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls
por: Rootman, Joseph M., et al.
Publicado: (2022)

Making waves: The changing tide of cerebral palsy
por: Cooper, Monica S, et al.
Publicado: (2022)

Good medical practice in a time of chronic disease: time to retrace our steps?
por: Bhopal, Anand
Publicado: (2016)

The Value Equation: Time for a Rethink!
por: Talluri, Nicholas, et al.
Publicado: (2020)

Math in the Time of Plague
por: Mazur, Barry
Publicado: (2020)

Successful Use of [(14)C]Paracetamol Microdosing to Elucidate Developmental Changes in Drug Metabolism
por: Mooij, Miriam G., et al.
Publicado: (2017)

Extinction Targets Are Not SMART (Specific, Measurable, Ambitious, Realistic, and Time Bound)
por: Hughes, Alice C, et al.
Publicado: (2020)

Motives and Side-Effects of Microdosing With Psychedelics Among Users
por: Hutten, Nadia R P W, et al.
Publicado: (2019)

Self-blinding citizen science to explore psychedelic microdosing
por: Szigeti, Balázs, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l34fpm6j90v3qdrfto9q0gvcf4